menu
    • menu
    [{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Inapplicable","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"The International Vaccine Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"The International Vaccine Institute \/ The International Vaccine Institute"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The International Vaccine Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"15","companyTruncated":"The International Vaccine Institute \/ The International Vaccine Institute"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The International Vaccine Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"The International Vaccine Institute \/ The International Vaccine Institute"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DuoChol","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The International Vaccine Institute \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"The International Vaccine Institute \/ Inapplicable"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"The Biovac Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Cholera Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The International Vaccine Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"4","companyTruncated":"The International Vaccine Institute \/ The International Vaccine Institute"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"TriLink BioTechnologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The International Vaccine Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"1","companyTruncated":"The International Vaccine Institute \/ The International Vaccine Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by The International Vaccine Institute

    Menu

    The International Vaccine Institute

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : TriLink BioTechnologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            TriLink & IVI Sign MoU to Support mRNA Vaccine Development Globally

                            Details : TriLink and IVI will collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 14, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : TriLink BioTechnologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DuoChol,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IVI Begins Clinical Development Of DuoChol Oral Cholera Vaccine

                            Details : DuoChol is a dry formulation in capsule form composed of inactivated bacterial whole cell/cholera toxin B subunit OCV. It is being developed as a vaccine candidate for cholera.

                            Product Name : DuoChol

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2023

                            Lead Product(s) : DuoChol,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCB-2019,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Clover Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infec...

                            Details : SCB-2019 (CpG 1018), a stabilized trimeric form of S-protein based on original strain of SARS-CoV-2 virus, demonstrated that household contact was 84% less likely to get SARS-CoV-2 infection when infected household member had received.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : SCB-2019,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Clover Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholera Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : The Biovac Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets

                            Details : The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes of OCV (cholera vaccines) in order to reduce the critical shortage of vaccines needed to prevent cholera globally.

                            Product Name : OCV

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Cholera Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : The Biovac Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV87,Aluminium Hydroxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IVI and BBIL Launch Global Chikungunya Vaccine Phase II/III trial in Costa Rica

                            Details : BBIL’s BBV87 vaccine is an inactivated whole virion vaccine based on strain derived from an East, Central, South African (ECSA) genotype. IVI is advancing clinical development of BBV87 to evaluate safety and immunogenicity of 2-dose regimen of BBV87 Ch...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 24, 2021

                            Lead Product(s) : BBV87,Aluminium Hydroxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            The International Vaccine Institute

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INO-4800,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Inovio Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            INOVIO, IVI to Start Ph 1/2 Trials of COVID-19 Vaccine in South Korea

                            Details : US based INOVIO, the International Vaccine Institute (IVI), and Seoul National University Hospital have entered a partnership to start a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine INO-4800 in South Korea.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 06, 2020

                            Lead Product(s) : INO-4800,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Inovio Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth